米非司酮联合米索前列醇治疗子宫内膜不典型增生的疗效观察

Efficacy observation of mifepristone and misoprostol in treatment of atypical endometrial hyperplasia

目的探讨米非司酮联合米索前列醇治疗子宫内膜不典型增生的临床疗效。方法选取2010年1月～2011年1月本院收治的子宫内膜不典型增生患者46例,将其随机分为观察组和对照组各23例,对照组采用单纯米非司酮治疗,观察组采用米非司酮联合米索前列醇治疗,两组均治疗3个月,治疗后观察两组的临床疗效、子宫内膜厚度变化情况及不良反应。结果治疗后观察组总有效率为91.30%,对照组为60.87%,两组总有效率差异有统计学意义(P<0.05)。治疗后观察组子宫内膜厚度为(1.75±0.28)mm,对照组为(6.32±0.45)mm,观察组明显低于对照组(P<0.05)。两组不良反应主要为恶心呕吐、眩晕乏力、下腹痛、闭经、潮红发热,差异无统计学意义(P>0.05)。结论米非司酮联合米索前列醇治疗子宫内膜不典型增生的效果优于单纯米非司酮治疗,安全有效,值得临床推广应用。

Objective To investigate the clinical efficacy of mifepristone and misoprostol in the treatment of atypical endometrial hyperplasia. Methods Forty-six cases of atypical endometrial hyperplasia patients were selected and divided into observation group and control group, 23 cases in each group. The control group were given mifepristone only, the observa- tion group were given mifepristone combined with misoprostol, the two groups were all treated for 3 months. After treatment, the clinical efficacy, endometrial thickness changes and adverse reactions were observed in two groups. Results The total efficacy rate of observation group was 91.30%, the control group was 60.87%, there was significant difference between the two groups （P 〈 0.05）. The endometrial thickness of observation group was （1.75±0.28） mm, which was lower than （6.32±0.45） mm of control group. The adverse reactions of two groups were nausea and vomiting, dizziness fatigue, lower abdominal pain, amenorrhea and flushing fever, the differences were not significant （P 〉 0.05）. Conclusion Mifepristone combined with misoprostol in the treatment of atypical endometrial hyperplasia has better efficacy than mifepristone only, it is safe and effective, be worthy of clinical application.